← Back to patent-cliff list
Kesonotide
Tier C — Watch / tradeKesonotide
Filamon Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：VIM
Indications (approved)：Lung cancer, Glioblastoma, Ovarian cancer, 皮肤肿瘤, Prostate cancer, Breast cancer, Pancreatic cancer, Inflammatory disease
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Kesonotide?
Approved indications include: Lung cancer, Glioblastoma, Ovarian cancer, 皮肤肿瘤, Prostate cancer, Breast cancer, Pancreatic cancer, Inflammatory disease.
When does the Kesonotide patent expire?
No public expiry year is available for Kesonotide yet; this page updates once verified.
How do I get a quote for Kesonotide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30